ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1385	National Cancer Institute	Html	en	Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing ovarian, fallopian tube, and primary peritoneal cancers and about research aimed at the prevention of them.	oral contraceptives 0.660699 untreated subfertile women 0.554695 population-based case-control study 0.569591 multiple case-control studies 0.577558 tubal ligation 0.612813 ovarian cancer subtypes 0.638647 endometrioid carcinomas 0.557685 Ovarian Cancer Association 0.647707 invasive ovarian tumors 0.625952 tubal intraepithelial carcinoma 0.613375 case-control studies 0.724549 modest increased risk 0.571056 ovarian cancer 0.933826 clear cell carcinomas 0.577194 oral contraceptive therapy 0.556361 ovarian carcinoma 0.65109 ovarian reserve 0.599754 ovarian borderline tumor 0.646023 low-grade ovarian carcinomas. 0.649208 ovarian primary tumors. 0.639278 high-grade carcinomas 0.568553 cohort studies 0.697042 hospital-based case-control studies 0.582441 ovarian cancer cases 0.640486	epithelial ovarian cancers 0.62928 women 0.680224 borderline ovarian tumors 0.627194 prospective cohort studies 0.573074 risk reduction 0.631051 cohort study 0.558817 ovarian carcinomas 0.707015 clear cell cancer 0.56063 ovarian cancers 0.642329 unexposed infertile women 0.555673 observed risk reduction 0.618238 ovarian hyperstimulation 0.617463 significant increased risk 0.567639 high-grade serous carcinomas 0.73533 fallopian tube 0.554218 epithelial ovarian cancer 0.644523 ovarian cancer risk 0.740549 epidemiological studies 0.565 population-based case-control studies 0.621559 gastrointestinal primary tumors 0.557125 Netherlands cohort study 0.55691 ovarian carcinoma subtypes 0.642907 meta-analysis 0.563338 systematic review 0.583056	CLICK HERE
1557	National Cancer Institute	Html	en	Colorectal Cancer Screening (PDQ®)–Patient Version	There are five types of tests that are used to screen for colorectal cancer: fecal occult blood test, sigmoidoscopy, colonoscopy, virtual colonoscopy, and DNA stool test. Learn more about these and other tests in this expert-reviewed summary.	PDQ Screening 0.618949 stool 0.590523 cancer treatment 0.582023 digital rectal exam 0.64051 ongoing clinical trials 0.583111 screening tests 0.63308 Different screening tests 0.618821 abnormal areas 0.580093 following PDQ summaries 0.632044 Cancer Information Service 0.620236 PDQ cancer information 0.80153 false-negative test result 0.583041 Colorectal Cancer Prevention 0.669028 positive test result 0.639633 Prevention Editorial Board 0.62622 treatment clinical trials 0.578891 National Cancer Institute 0.708875 clinical trials 0.776593 colorectal cancer screening 0.731391 PDQ documents 0.584043 tube-like instrument 0.57905 test result 0.671884 cancer information summary 0.700249 clinical trial 0.586822	new treatment 0.582243 breast cancer prevention 0.604538 colorectal cancer 0.988753 Cancer screening trials 0.664201 false-positive test result 0.582754 new colorectal cancer 0.672245 colon cancer 0.621374 colorectal cancer help 0.669499 fecal immunochemical test 0.586261 Cancer Care page 0.608301 PDQ database 0.587115 latest published information 0.582352 NCI’s PDQ 0.590817 virtual colonoscopy 0.681415 PDQ summary 0.644281 cancer symptoms 0.598532 NCI PDQ cancer 0.66186 tests 0.64391 cancer information summaries 0.626981 special card 0.600211 comprehensive cancer information 0.626204 occult blood test 0.58711 rectum 0.607195	CLICK HERE
1624	National Cancer Institute	Html	en	Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of Wilms tumor.	wilms tumor 0.926034 treatment 0.447725 malignant tumor cells 0.243725 cancer treatment 0.217156 abdomen 0.245624 NCI-supported cancer 0.203382 cancer cells 0.312954 body 0.284934 type 0.202622 chemotherapy 0.265514 kidney 0.420084 clinical trial search 0.271589 PDQ Wilms Tumor 0.212419 clinical trials 0.537885 Wilms tumor spreads 0.21053 Wilms tumor depend 0.213963	clinical trial 0.332838 renal cell cancer 0.378864 combination chemotherapy 0.254074 blood 0.211019 PDQ summary 0.204133 metastatic Wilms tumor 0.210734 cancer clinical trials 0.268102 lymph nodes 0.354558 congenital mesoblastic nephroma 0.200441 anaplastic Wilms tumor 0.26619 radiation therapy 0.416592 rhabdoid tumor 0.263616 cancer 0.757965 information 0.244245 Wilms tumor cells 0.224035 childhood kidney tumors 0.354935	CLICK HERE
1794	National Cancer Institute	Html	es	El dolor y el cáncer (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del dolor como una complicación a causa del cáncer o su tratamiento. Se tratan abordajes para el control y el tratamiento del dolor relacionado con el cáncer.	PDQ Complicaciones 0.575413 edad avanzada.Dosis 0.516499 Physician Data Query 0.512343 Estados Unidos 0.550291 radioterapia ayuda 0.539968 siguientes tipos 0.59269 libre uso 0.498177 vía oral 0.816108 ¿El dolor 0.996907 largo plazo 0.526626 siguientes observaciones 0.519179 Cancer Institute 0.496567	siguientes exámenes 0.600861 pacientes quizás 0.564494 familia instrucciones 0.559775 síndrome mano-pie 0.573945 siguientes medicamentos 0.524062 siguientes momentos 0.614035 empeoramiento pasajero 0.644072 siguientes sumarios 0.581267 PDQ Acupuntura 0.539252 vía iv 0.553442 Institutos Nacionales 0.504308	CLICK HERE
1840	National Cancer Institute	Html	es	Tratamiento de la enfermedad trofoblástica de la gestación (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la enfermedad trofoblástica de la gestación.	Obstet Gynecol 0.314049 calificación pronóstica 0.330592 Agarwal R 0.309981 gestational trophoblastic tumor 0.470216 gynecologic oncology 0.31949 gestational trophoblastic tumour 0.330225 Sin embargo 0.495025 largo plazo 0.308011 drug-resistant gestational trophoblastic 0.316646 trophoblastic tumor simulating 0.31025 gestational trophoblastic 0.969098 high-risk gestational trophoblastic 0.417868 site trophoblastic tumor 0.331006 Epithelioid trophoblastic tumor 0.331525 oncology group study 0.309029 retrospective observational study 0.310708 trophoblastic neoplasia with 0.311489 trophoblastic tumor 0.525373 newlands es 0.321142 gestational trophoblastic neoplasia 0.524164 Gynecol Oncol 0.321149 Database Syst Rev 0.308864 placental site trophoblastic 0.326491 chemorefractory gestational trophoblastic 0.316598 Reprod Med 0.395131	gynecologic oncology group 0.309183 Lancet Oncol 0.308542 Organización Mundial 0.310432 tumores trofoblásticos epitelioides 0.326002 Lurain JR 0.332449 metastatic gestational trophoblastic 0.30963 Holden L 0.308229 Cancer Staging Manual 0.311272 Féderation Internationale 0.320433 trophoblastic disease 0.450228 with gestational trophoblastic 0.311191 trophoblastic tumours 0.335737 Recurrent gestational trophoblastic 0.309132 Clin Oncol 0.324887 sistema nervioso central 0.319546 low-risk gestational trophoblastic 0.340233 Charing Cross 0.316962 Gynaecol Obstet 0.314146 persistent gestational trophoblastic 0.309878 Short D 0.308931 FIGO Committee 0.309443 Charing Cross Hospital 0.309844 Obstet Gynaecol 0.310271 AJCC Cancer Staging 0.31188	CLICK HERE
1852	National Cancer Institute	Html	es	Tratamiento del sarcoma de Kaposi (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del sarcoma de Kaposi.	Kaposi sarcoma with 0.314018 preventing kaposi 0.313966 Moritz Kaposi 0.309028 Trials Group Oncology 0.302538 Kaposi africano 0.309508 cutaneous aids-related kaposi 0.30771 kaposi's sarcoma 0.991554 progressive aids-related kaposi 0.307625 sarcoma with paclitaxel 0.306043 herpesvirus-like dna 0.302234 survival among hiv-infected 0.302423 treatment with high 0.30236 classic kaposi 0.311511 beam therapy 0.302479 Radiat Oncol Biol 0.305359 highly active 0.305764 aids-related kaposi sarcoma 0.417048 Kaposi's sarcoma-associated 0.30807 Kaposi's sarcoma from 0.313495 immunodeficiency virus-associated kaposi 0.30747 Natl Cancer Inst 0.305462 active antiretroviral therapy 0.313159 epidemic kaposi sarcoma 0.312845 AIDS-associated Kaposi sarcoma 0.331004 patients with 0.308166	radiation therapy 0.302199 Oral Kaposi sarcoma 0.311958 SK pulmonares 0.30414 Group Oncology Committee 0.302045 Kaposi's sarcoma with 0.379286 with kaposi 0.308785 HIV-associated Kaposi sarcoma 0.319062 Clinical Trials Group 0.322249 pegylated liposomal doxorubicin 0.307131 Kaposi's sarcoma receiving 0.31211 Kaposi's Sarcoma Study 0.313825 acquired immunodeficiency 0.307622 Oncology Committee 0.302366 non-visceral classic kaposi 0.307333 cutaneous kaposi 0.311944 trasplante renal 0.302536 AIDS Clinical Trials 0.324534 Clin Oncol 0.347601 resembling kaposi 0.307994 Oncol Biol Phys 0.305455 Pulmonary Kaposi sarcoma 0.312483 lesiones cutáneas 0.312534 Safai B 0.309301 acquired immune deficiency 0.302495	CLICK HERE
1853	National Cancer Institute	Html	es	Tratamiento de los tumores de hipófisis (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de hipófisis.	pituitary tumors 0.728644 apoplejía hipofisaria 0.422211 general adenomas gonadotropos 0.447102 gonadotroph adenomas 0.512689 Sin embargo 0.480821 pituitary carcinoma 0.526345 adenomas lactótropos 0.483762 Endocrinol Invest 0.422936 tumores gonadotropos 0.422871 tumores celulares productores 0.42814 tumores productores 0.449036 Couldwell WT 0.451028 Asa SL 0.451558 tumores endocrinos 0.42423 adenomas corticotropos 0.483433 Di Sarno A 0.42917 Kovacs KT 0.42311 Clin Endocrinol Metab 0.711638 ACTH secreting pituitary 0.441137 Neurosurg Focus 0.422719 adenomas gonadotropos 0.63232 Yeh PJ 0.462771 Chen JW 0.457982 case report 0.519998 Ezzat S 0.451653	Levy A 0.45572 adenomas tirotropos 0.47717 Long-term survival with 0.423122 pituitary adenoma 0.992345 Scheithauer BW 0.524034 invasive pituitary tumors 0.460006 adenomas somatotropos 0.480811 Subclinical adenomas 0.440961 Surg Oncol 0.463881 to functional classification 0.441148 occult adenomas 0.439818 secreting pituitary neoplasia 0.430766 Neurol Neurosurg Psychiatry 0.513976 Colao A 0.424448 Kovacs K 0.448425 with acth-secreting carcinoma 0.427044 systematic review 0.423136 Laws ER Jr 0.437305 pituitary tumors with 0.465003 medical management 0.455666 thyrotropin-secreting pituitary adenoma 0.457958 Adenomas benignos 0.45094 hipófisis productores 0.733158 Horvath E 0.435361	CLICK HERE
1895	National Cancer Institute	Html	null	Tratamiento del cáncer de pulmón de células pequeñas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células pequeñas.			CLICK HERE
15635	National Cancer Institute	Html	en	Step 4: Award Negotiation & Issuance	Before a grant can be awarded and accepted, several pre-award activities must happen to formalize the partnership. Ensuring compliance with federal laws, a review of costs and a negotiation of the appropriate funding level must all happen in order to rece	applicant institution 0.49498 NoA 0.545113 NIH eRA Commons 0.538439 HHS requirements 0.455116 applicant’s business 0.43403 special terms 0.42079 business/administrative management perspective 0.537644 initial budget period 0.503089 grants management specialist 0.84443 subsequent budget periods 0.62245 NIH official 0.455564 multiple pre-award activities 0.51965 award 0.677162 post-award process 0.430443 Grants Administration staff 0.556889 pre-award process 0.432795 terms 0.443034 Noncompeting Award Process 0.543798 special conditions 0.423887 new recipient requirements 0.531908 research staff 0.423565 Associated F&A costs 0.474288 HHS Congressional Liaison 0.509654	grants management 0.935861 NIH Grants Policy 0.596078 specialized terms 0.42458 grants specialist 0.462503 categorical budget 0.451864 NCI staff 0.518462 award information 0.450047 management officer certifies 0.491818 awarding office 0.423573 HHS Payment Management 0.546384 NIH GPS 0.461713 overall scientific endeavor 0.511733 review recommendations 0.498295 Initial peer review 0.489678 grants management officer 0.679819 budget category 0.426444 NIH Office 0.466998 institute special monitoring 0.484399 policy requirements 0.426959 appropriate funding level 0.509975 pre-award negotiation process 0.500978 legally binding requirements 0.48831 award notices 0.446172	CLICK HERE
16649	National Cancer Institute	Html	en	Track 4: Cancer Prevention Product Research and Review for Postdoctoral Research Fellows	NCI and FDA collaborate to train individuals in the medical product development and application process. Learn more about this cancer training program.	regulatory research 0.47135 pharmacology/toxicology branch 0.439495 cancer prevention trials 0.576995 limited preclinical data 0.531474 NCI fellows 0.61137 non-clinical fellows 0.591774 FDA scientific review 0.564313 related regulatory experience 0.528845 Fellowship Program 0.512424 IRB approval process 0.551558 treatment endpoints 0.45623 application guidelines 0.486651 clinical trials 0.471521 translational research 0.452228 research goals 0.442846 early detection 0.562481 early detection trials 0.555324 various regulatory activities 0.534652 acceptable drug toxicity 0.528586 Regulatory Review Fellowships 0.520225 approval processes 0.437768 multidisciplinary cancer prevention 0.570632 particular product division 0.535827 FDA Centers 0.561203	research mentors 0.452404 product standards 0.439879 Cancer Prevention Fellowship 0.546138 regulatory pathways 0.442598 professional development activities 0.534321 earliest start date 0.490036 cancer prevention 0.942415 critical ethical issues 0.519948 product research 0.479994 clinical investigation 0.441391 appropriate clinical endpoints 0.603566 Effective Presentations Workshop 0.512774 human research subjects 0.569744 guidance document development 0.508388 public health 0.546598 Fellowship Program staff 0.506185 NCI-FDA Research 0.441603 Molecular Prevention Laboratory 0.53668 cancer prevention research 0.787983 research interests 0.453508 device development 0.439712 chemoprevention trials 0.587824 research-related regulatory overview 0.574022 Fellows Research Meetings 0.732161	CLICK HERE